SCHEMBL13015010

SCHEMBL13015010

Cc1ccc(-c2c3ccc4cc(O)ccc4c3oc3c2ccc2cc(=O)ccc23)c(C(=O)O)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.74
USP2 O75604 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40
MAOA P21397 1/20 0.37
CA1 P00915 5/20 0.37
CA2 P00918 4/20 0.37
CA9 Q16790 4/20 0.37
CSNK2A1 P68400 1/20 0.37
ATM Q13315 1/20 0.37
PLEC Q15149 1/20 0.37
DNASE1L3 Q13609 1/20 0.36
PRMT1 Q99873 1/20 0.36
CA12 O43570 3/20 0.36
CA4 P22748 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13180156 0.88 SOS1 (0.76) SOS1USP2L3MBTL1POLBMEN1
SCHEMBL29544864 0.88 SOS1 (0.76) SOS1USP2L3MBTL1POLBMEN1
SCHEMBL10059473 0.85 SOS1 (1.00) SOS1USP2L3MBTL1POLBMEN1
SCHEMBL15277723 0.82 SOS1 (0.67) SOS1USP2L3MBTL1POLBMEN1
SCHEMBL29543257 0.81 SOS1 (0.76) SOS1USP2L3MBTL1POLBMEN1
SCHEMBL17312264 0.81 SOS1 (0.76) SOS1USP2L3MBTL1POLBMEN1
SCHEMBL13180154 0.78 SOS1 (0.59) SOS1USP2L3MBTL1CA9
SCHEMBL17254331 0.78 SOS1 (0.62) SOS1USP2L3MBTL1POLBMEN1
SCHEMBL14385634 0.78 USP2 (0.47) SOS1USP2L3MBTL1POLBMEN1
SCHEMBL2737206 0.78 SOS1 (0.85) SOS1USP2L3MBTL1POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372868-B2 Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging VANDERBILT UNIVERSITY (US) 2013-02-12 US disclosed
US-20100324130-A1 DAA PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR CANCER IMAGING AND TREATMENT US ARMY, SECRETARY OF THE ARMY 2010-12-23 US disclosed
US-20100278739-A1 TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING VANDERBILT UNIVERSITY 2010-11-04 US disclosed
US-7754884-B2 Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging VANDERBILT UNIVERSITY (US) 2010-07-13 US disclosed
US-20080031823-A1 AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING US GOVERNMENT - SECRETARY FOR THE ARMY 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080031823-A1 AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING TSPO, MKI67, CNR1 SOS1 3082/4885USP2 3974/4885L3MBTL1 2590/4885
US-20100324130-A1 DAA PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR CANCER IMAGING AND TREATMENT GABRA6, GABRA1, GABRA4 SOS1 3077/4885USP2 2333/4885L3MBTL1 3119/4885
US-20100278739-A1 TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING TSPO, MKI67, GABRA4 SOS1 3651/4885USP2 2908/4885L3MBTL1 2678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.